Form 8-K - Current report:
SEC Accession No. 0001213900-24-110191
Filing Date
2024-12-18
Accepted
2024-12-18 17:00:09
Documents
15
Period of Report
2024-12-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0225021-8k_adialpharm.htm   iXBRL 8-K 54607
2 PURCHASE AGREEMENT, DATED AS OF DECEMBER 13, 2024, BY AND BETWEEN ADIAL PHARMACE ea022502101ex10-1_adialpharm.htm EX-10.1 146589
3 TERMINATION AGREEMENT, DATED AS OF DECEMBER 13, 2024, BY AND BETWEEN ADIAL PHARM ea022502101ex10-2_adialpharm.htm EX-10.2 9468
  Complete submission text file 0001213900-24-110191.txt   427220

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adil-20241213.xsd EX-101.SCH 3006
5 XBRL LABEL FILE adil-20241213_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE adil-20241213_pre.xml EX-101.PRE 22353
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0225021-8k_adialpharm_htm.xml XML 3657
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 241560079
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)